The primary endpoint for Arms A and B were met by demonstrating tumor specimens from resected PDA patients treated with nivolumab and Cy-GVAX had significantly increased IL17A expression/TH17 infiltration in TLAs compared to tumor specimens from PDA patients treated with Cy-GVAX alone and was reported as part of correlative studies with Arms A and B, previously (19). The gene discussed is IL17A; the disease is Patent ductus arteriosus.